Is complement a target for therapy in renal disease?

被引:14
作者
Mathieson, PW [1 ]
机构
[1] Southmead Gen Hosp, Acad Renal Unit, Bristol BS10 5NB, Avon, England
关键词
glomerulonephritis; treatment; soluble CR1; xenotransplantation; immunotherapy;
D O I
10.1046/j.1523-1755.1998.00129.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Complement deposition in the injured kidney is common, especially in glomerulonephritis. The precise role of the complement system in the mediation of tissue injury in the kidney has been defined in recent years, and this has assumed extra importance with the recent development of specific forms of therapy directed at the complement pathway. As well as the induction of cell lysis, complement has many subtle effects on cell biology, particularly on endothelial cells. Complement components are produced locally in the kidney. Detailed studies of certain rare forms of nephritis have provided evidence that complement activation can directly cause tissue injury. Appreciation of the importance of complement in hyperacute rejection of xenotransplants has given new impetus to the development of complement inhibitors. A narrative review is provided, with a brief overview of the complement pathway and its regulatory mechanisms, mechanisms of complement-induced tissue injury, local complement production, and the renal consequences of complement dysregulation. Currently available forms of therapy aimed at the complement system are reviewed, and possible future therapeutic strategies are suggested. The complement system plays a direct causal role in tissue injury in certain forms of renal disease. Specific forms of therapy are becoming available that can selectively interrupt complement activation or promote its regulation. Much of the drive for the development of these therapies comes from the field of xenotransplantation, but these forms of therapy should also be tested in various primary renal diseases.
引用
收藏
页码:1429 / 1436
页数:8
相关论文
共 70 条
[1]   COMPLEMENT MEMBRANE ATTACK COMPLEX STIMULATES PRODUCTION OF REACTIVE OXYGEN METABOLITES BY CULTURED RAT MESANGIAL CELLS [J].
ADLER, S ;
BAKER, PJ ;
JOHNSON, RJ ;
OCHI, RF ;
PRITZL, P ;
COUSER, WG .
JOURNAL OF CLINICAL INVESTIGATION, 1986, 77 (03) :762-767
[2]   Human factor H deficiency - Mutations in framework cysteine residues and block in H protein secretion and intracellular catabolism [J].
Ault, BH ;
Schmidt, BZ ;
Fowler, NL ;
Kashtan, CE ;
Ahmed, AE ;
Vogt, BA ;
Colten, HR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (40) :25168-25175
[3]  
BAKER PJ, 1989, AM J PATHOL, V135, P185
[4]   Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies [J].
Botto, M ;
Dell'Agnola, C ;
Bygrave, AE ;
Thompson, EM ;
Cook, HT ;
Petry, F ;
Loos, M ;
Pandolfi, PP ;
Walport, MJ .
NATURE GENETICS, 1998, 19 (01) :56-59
[5]   Role of the complement membrane attack complex (C5b-9) in mediating experimental mesangioproliferative glomerulonephritis [J].
Brandt, J ;
Pippin, J ;
Schulze, M ;
Hansch, GM ;
Alpers, CE ;
Johnson, RJ ;
Gordon, K ;
Couser, WG .
KIDNEY INTERNATIONAL, 1996, 49 (02) :335-343
[6]   Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis [J].
Clynes, R ;
Dumitru, C ;
Ravetch, JV .
SCIENCE, 1998, 279 (5353) :1052-1054
[7]   MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS IN DOGS WITH A GENETICALLY-DETERMINED DEFICIENCY OF THE 3RD COMPONENT OF COMPLEMENT [J].
CORK, LC ;
MORRIS, JM ;
OLSON, JL ;
KRAKOWKA, S ;
SWIFT, AJ ;
WINKELSTEIN, JA .
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1991, 60 (03) :455-470
[8]  
COSIO FG, 1985, LANCET, V2, P118
[9]   LOCALIZATION OF DECAY ACCELERATING FACTOR IN NORMAL AND DISEASED KIDNEYS [J].
COSIO, FG ;
SEDMAK, DD ;
MAHAN, JD ;
NAHMAN, NS .
KIDNEY INTERNATIONAL, 1989, 36 (01) :100-107
[10]  
COULPIER M, 1995, CLIN EXP IMMUNOL, V101, P142